

MAR 29, 2024

Company: Chiome Bioscience Inc.

Representative: Shigeru Kobayashi, President & CEO

(Code: 4583, Tokyo Stock Exchange Growth)

### **Termination of License Agreement with ADC Therapeutics**

Chiome Bioscience Inc. (“Chiome”) announced today the termination of the license agreement with ADC Therapeutics (“ADCT”) for LIV-1205 (“License Agreement for anti-DLK-1 antibody development and commercialization” dated September 27, 2017, and “Amendment to the License Agreement with ADC Therapeutics” dated November 10, 2020 (collectively “the Agreements”)).

Under the Agreements, our company granted ADCT the worldwide, exclusive, sub-licensable right for development, manufacturing and marketing of anti-DLK-1 antibody limited to antibody-drug conjugates (ADCs) using PBDs. In May 2023 ADCT announced that it would prioritize investment upon its marketed product and its later stage pipeline, ADCT decided to halt investment on ADCT-701 development, However NCI, with whom ADCT had a CRADA, will sponsor a Phase I clinical study of ADCT-701. Under these circumstances, both ADCT and Chiome agreed to terminate the Agreements. Upon completion of the termination of the Agreements, Chiome will own all rights related to LIV-1205.

NCI plans to conduct a Phase I study in neuroendocrine cancers using the clinical drug supply provided by ADCT. The study is ready to commence. Any future development beyond Phase I would necessitate obtaining a license to LIV-1205 from Chiome.

There is no impact on the financial performance ending December 31, 2024.

#### <About ADCT-701>

ADCT-701 is an ADC (Antibody-Drug-Conjugate) that ADCT developed with a cytotoxic PBD payload conjugated with LIV-1205 (anti-DLK-1 antibody) invented by Chiome. An IND application has been filed by NCI for the start of Phase I study, and NCI plans to start clinical the study\* during 2024.

\*: NCI06041516

#### <About CRADA>

Cooperative Research and Development Agreement (CRADA) is any formal written agreement between one or more Federal laboratories and one or more non-Federal parties under which the government, through its laboratories, provides personnel, services, facilities, equipment, intellectual property, or other resources.

#### **【Inquiries】**

Chiome Bioscience Inc. Investor Relations

E-mail:ir@chiome.co.jp